by KeAi Communications Co. Animal study flowchart and schematic illustration of sequential USMI. Credit: Liver Research (2023). DOI: 10.1016/j.livres.2023.11.002Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH). Invasive liver biopsy continues to be the gold standard...
Tag: <span>NASH</span>
Post
TGF-β-driven reduction of CYGB is associated with oxidative DNA damage of HSCs in NASH
In the 2020 April 21 issue of Journal of Hepatology, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that a new insight into the pathophysiology of human nonalcoholic steatohepatitis (NASH) with fibrosis and suggested a possibility of the new therapy using cytoglobin (CYGB) inducer for...
Post
Two enzymes control liver damage in NASH, study shows
by University of California – San Diego As much as 12 percent of adults in the United States are living with nonalcoholic steatohepatitis (NASH), an aggressive condition that can lead to cirrhosis or liver cancer. After identifying a molecular pathway that allows NASH to progress into liver cell death, University of California San Diego School...